Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours

BACKGROUND: JNJ-26483327 is an oral, potent, multi-targeted tyrosine kinase inhibitor, inhibiting kinases of epidermal growth factor receptor (EGFR)-1, -2 and -4, rearranged during transfection (RET) receptor, vascular endothelial growth factor receptor (VEGFR)-3 and Src family (Lyn, Fyn, Yes) at lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Konings, I R H M, de Jonge, M J A, Burger, H, van der Gaast, A, van Beijsterveldt, L E C, Winkler, H, Verweij, J, Yuan, Z, Hellemans, P, Eskens, F A L M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2965873/
https://www.ncbi.nlm.nih.gov/pubmed/20823884
http://dx.doi.org/10.1038/sj.bjc.6605867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2965873/
https://www.ncbi.nlm.nih.gov/pubmed/20823884
http://dx.doi.org/10.1038/sj.bjc.6605867

Ejemplares similares